Mounjaro NHS Eligibility Criteria: Do You Qualify?

The decision you're actually making: NHS route or private route?

Before looking at the specific thresholds, it helps to name the real choice. If you're reading about Mounjaro NHS eligibility criteria, you're probably weighing two paths: waiting to see whether the NHS will prescribe it for you, or accessing it privately now through a regulated clinical service. Neither is a shortcut and neither is the wrong answer, they serve different situations.

The NHS route costs nothing for the medicine, but the criteria are strict, participation by GP practices is optional, and the wrap-around lifestyle programme is a condition of treatment rather than a nice-to-have. Our overview of NHS Mounjaro eligibility sets out exactly what the programme involves. The private route means paying for treatment, but there are no referral hoops, no waiting list, and a prescriber reviews your case the same day. Knowing which camp you fall into starts with understanding the NHS thresholds in detail.

The phased NHS thresholds, where things stand right now

NICE recommended tirzepatide (Mounjaro) for NHS use in December 2024, and NHS England has been rolling out access in stages ever since. NICE technology appraisal TA1026 sets the clinical framework; NHS England translates that into commissioning cohorts.

The first cohort, active from June 2025, requires a BMI of 40 or above alongside four or more of the five qualifying conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. The second cohort was activated on 23 June 2026 and covers a BMI of 35 to 39.9 combined with the same four-condition requirement. A third cohort, expected around March 2027, will lower the condition count to three for those with a BMI of 40 or above.

For some ethnic backgrounds (including South Asian, Chinese, other Asian, Middle Eastern, Black African, and African-Caribbean) thresholds are 2.5 kg/m² lower at every cohort stage. The updated 2026 criteria page goes through each cohort and the adjusted thresholds in full. If you want to check your own BMI before reading further, the NHS BMI calculator takes under a minute to use.

Meeting the BMI and condition count is necessary but not sufficient. Every qualifying patient must also take part in an NHS-commissioned wrap-around diet and physical activity programme. And because GP practice participation in the QOF 2026/27 contract is voluntary, availability varies depending on where you live.

What happens when you meet some criteria but not all

This is where most people get stuck. Perhaps your BMI sits at 38 and you have three of the five conditions. Or your BMI is over 40 but only two conditions are documented in your record. Under current NHS criteria, neither scenario qualifies for Cohort 1 or 2, and Cohort 3 won't open until 2027.

There's also a documentation question worth raising with your GP: conditions need to appear in your medical record to count. If sleep apnoea is suspected but undiagnosed, or dyslipidaemia has never been formally recorded, the count may fall short on paper even when the clinical picture is clear. A practical habit worth building: log into your NHS App and review your listed conditions before any GP conversation about Mounjaro. It takes about sixty seconds and can clarify exactly where you stand.

People in this position often look at the private route. The 2025 NHS criteria summary covers the earlier cohort detail for context, and our weight-loss NHS criteria page explains how the private licensed thresholds differ from NHS ones.

The private licensed criteria, and what nume's process involves

Through a private regulated service, the licensed eligibility for Mounjaro is broader: adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as prediabetes, hypertension, high cholesterol, or obstructive sleep apnoea. These follow the medicine's SmPC, not NHS commissioning rules, and if you're curious whether you can get more than one pen at a time, our page on whether you can order two Mounjaro pens at once explains how that works in practice. A prescriber still makes the final decision, the BMI figure is the starting point, not the approval itself.

At nume, a GPhC-registered Independent Prescriber reviews every consultation personally. There's no algorithm reading your answers; a real clinician considers the full clinical picture, including any medicines you take and your medical history. Identity and current weight are verified before anything is dispensed. If you're already on treatment elsewhere and considering a transfer, our prescribers review evidence of your current dose before continuing. For a fuller picture of how the private route compares on cost, the context around Mounjaro's UK pricing is worth reading alongside this, as is our dedicated page covering the full Mounjaro NHS criteria if you want to revisit the clinical thresholds in one place.

Tirzepatide is a prescription-only medicine. Getting the prescription right matters as much as getting the medicine. If you'd like a prescriber to assess whether treatment is appropriate for your situation, you can speak to our prescribers through a free consultation, no commitment, no waiting list.